Rate and time dependent effects of D-sotalol on the monophasic action potential after sudden increase of the heart rate

PACE - Pacing and Clinical Electrophysiology

Volumn 22, Issue 1 I, 1999, Pages 65-72

  Melichercik, Juraj ^a   Brachmann, Johannes ^b   Schöls, Wolfgang ^b   Hilbel, Thomas ^b   Beyer, Thorsten ^b   Kübler, Wolfgang ^b  

^a Heart Institute Lahr/Baden   (Germany)

^b NONE

Author keywords

Cardiac refractoriness; Cardiac repolarization; D sotalol; Monophasic action potential; Ventricular tachyarrhythmias

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALMOKALANT; AMBASILIDE; CLOFILIUM; DOFETILIDE; DRONEDARONE; IBUTILIDE; RISOTILIDE; SEMATILIDE; SOTALOL; TEDISAMIL; TERIKALANT; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HEART ARRHYTHMIA; HEART MUSCLE REFRACTORY PERIOD; HEART RATE; HEART VENTRICULOGRAPHY; HUMAN; MALE; TACHYCARDIA;

ACTION POTENTIALS; AGED; ANTI-ARRHYTHMIA AGENTS; CARDIAC PACING, ARTIFICIAL; ELECTROPHYSIOLOGY; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; SOTALOL; TACHYCARDIA, VENTRICULAR;

EID: 0032898982     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1999.tb00301.x     Document Type: Article

References (51)

1. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo; the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
2. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
3. Waldo AL, Camm AJ, de Ruyter H, et al. Preliminary mortality results from the survival with oral d-sotalol (SWORD) trial. J Am Coll Cardiol 1995; 25:15A.
4. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994; 9:12-22.
5. Singh BN. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: Particular reference to sotalol. Am J Cardiol 1990; 65:3A-11A.
6. Rasmussen HS, Allen MJ, Blackburn KJ, et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992; 20:96-105.
7. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion. Am J Cardiol 1992; 70:1432-1437.
8. Honerjäger P, Schmidt G. New antiarrhythmic agents. Z Kardiol 1992; 81:133-137.
9. Watanabe I, Kojima T, Kondo K, et al. Frequency dependent electrophysiologic effects of amiodarone and E-4031, a "pure" class III antiarrhythmic agent. Circulation 1992; 86(Suppl):1718.
10. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993; 72:44B-49B.
11. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation; differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994; 90:2032-2040.
12. Buchanan LV, Kabell G, Brunden MN, et al. Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68, 798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993; 22:540-549.
13. Ishii Y, Muraki K, Kurihara A, et al. Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium. Jpn J Pharmacol 1995; 68:175-182.
14. Sager PT, Nademanee K, Antimisiaris M, et al. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic action of Sematilide HCl in humans. Circulation 1993; 88:1072-1082.
15. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Circulation 1990; 82:2235-2242
16. + channels in rat and guinea pig ventricular myocytes. Circulation 1989; 80:SII-517.
17. +)-sotalol in the anesthetized dog. J Cardiovasc Pharmacol 1992; 20:458-465.
18. + current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol 1992; 20:106-113.
19. Follmer CH, Poczobutt MT, Colatsky TJ. Selective block of delayed rectification (Ik) in feline ventricular myocytes by WY 48, 986, a novel class III antiarrhythmic agent. J Mol Cell Cardiol 1989; 21(Suppl II):185.
20. Manning AS, Bruyninckx C, Ramboux J, et al. SR 33589, a new amiodarone-like agent: Effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995; 26:453-461.
21. Advani SV, Singh BN. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol. Drugs 1995; 49:664-679.
22. Brachmann J, Beyer T, Schmitt C, et al. Electrophysiologic and antiarrhythmic effects of d-Sotalol. J Cardiovasc Pharmacol 1992; 20:91-95.
23. McComb JM, McGovern B, McGowan JB, et al. Electrophysiologic effects of d-sotalol in humans. J Am Coll Cardiol 1987; 10:211-217.
24. Schwartz J, Crocker K, Wynn J, et al. The antiarrhythmic effects of d-sotalol. Am Heart J 1987; 114:539-544.
25. Taggart P, Sutton P, Donaldson R. D-sotalol: A new potent class III antiarrhythmic agent. Clin Sci 1985; 69:631-636.
26. Brachmann J, Schmitt C, Schöls W, et al. Acute antiarrhythmic efficacy of iv. and oral d-sotalol in patients with sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1992; 19:244A.
27. Koch KT, Duren DR, van Zwieten PA. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction. Cardiovasc Drugs Ther 1995; 9:437-443.
28. Sahar DI, Reiffel JA, Bigger T, et al. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. Am Heart J 1989; 117:562-568.
29. Singh BN. Antiarrhythmic actions of d,l-sotalol in ventricular and supraventricular arrhythmias. J Cardiovasc Pharmacol 1992; 20:75-90.
30. Singh BN. Expanding indications for the use of class III agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 1995; 6:887-900.
31. Huikuri HV, Yli-Mäyry S. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. PACE 1992; 15:2103-2106.
32. Yuan S, Wohlfart B, Rasmussen HS, et al. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. Eur Heart J 1994; 15:514-522.
33. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation 1990; 81:686-690.
34. Shimizu W, Kurita T, Suyama K, et al. Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings. Am J Cardiol 1996; 1:1004-1008.
35. Schmitt C, Beyer T, Karch M, et al. Sotalol exhibits reverse use-dependent action on monophasic action potentials in normal but not in infarcted canine ventricular myocardium. J Cardiovasc Pharmacol 1992; 19:487-492.
36. Schmitt C, Brachmann J, Karch M, et al. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potential of the right ventricle. Am J Cardiol 1991; 68:1183-1187.
37. Franz MR. Method and theory of monophasic action potential recording. Prog Cardiovasc Dis 1991; 33:347-368.
38. Franz MR, Schaefer J, Schöttler W, et al. Electrical and mechanical restitution of the human heart at different rates of stimulation. Circ Res 1983; 53:815-822.
39. Kanaan N, Jenkins J, Childs K, et al. Monophasic action potential duration during programmed electrical stimulation. PACE 1991; 14:1049-1059.
40. Seed WA, Noble MIM, Oldershaw P, et al. Relation of human cardiac action potential duration to the interval between beats: Implications for the validity of rate corrected (QTc) Br Heart J 1987; 57:32-37.
41. Franz MR, Swerdlow CD, Liem LB, et al. Cycle length dependence of human action potential duration in vivo. J Clin Invest 1988; 82:972-979.
42. Escande D, Henry P. Potassium channels as pharmacological targets in cardiovascular medicine. Eur Heart J 1993; 14:2-9.
43. Kiehn J, Lacerda AE, Wible B, et al. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996; 94:2572-2579.
44. Schmitt C, Schreieck J, Karch M, et al. Frequency-dependent effects of class III antiarrhythmic agents as assessed by MAP recordings - Possible advantages of Iks blockade. In MR Franz, C Schmitt, B Zrenner (eds.): Monophasic Action Potentials. Heidelberg, Germany, Springer-Verlag Berlin, 1997, pp. 85-96.
45. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier current by dofetilide. Circ Res 1993; 72:75-83.
46. kr. Implications for Torsade de pointes and reverse use-dependence. Circulation 1996; 93:407-411.
47. Zeng JZ, Laurita KR, Rosembaum DS, et al. Two components of the delayed rectifier K+ current in ventricular myocytes of the guinea pig type. Theoretical formulation and their role in repolarization. Circ Res 1995; 77:140-152.
48. Weirich J. Rate dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. In MR Franz, C Schmitt, B Zrenner (eds.): Monophasic Action Potentials. Heidelberg, Germany, Springer-Verlag, Berlin, 1997, pp. 71-84.
49. Weirich J, Hohnloser S, Dieterle T, et al. Reverse use-dependence of d-sotalol is consistent with slow on- and off-kinetics of a periodical interaction with potassium channels. Arch Pharmacol 1992; 345:R71.
50. Weirich J, Hohnloser S, Antoni H. D-sotalol and dofetilide exhibits slow offset kinetics: Significance for their antifibrillatory efficacy. PACE 1994; 17(SupplII):332.
51. Woosley RL, Barbex JT, Wang T, et al. Concentration/response relations for the multiple antiarrhythmic actions of sotalol. Am J Cardiol 1990; 65.-22A-27A.